ESMO 2025 Videos

Phase 3 INDICATE Trial for Patients with Biochemically Recurrent Prostate Cancer - Neha Vapiwala

Biomarker Data from Phase II PT-112 Trial in Heavily Pretreated mCRPC - Alan Bryce

Phase 3 KEYNOTE-905 Trial Investigates Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Christof Vulsteke

ALBAN Trial Analysis: Evaluating Atezolizumab Addition to BCG Therapy in High-Risk, Non-Muscle-Invasive Bladder - Morgan Rouprêt

Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria De Santis

Phase 1 Dosing Strategy and Translational Findings for Investigational Therapy Pasritamig - Karen Autio

Phase II NESCIO Trial of Neoadjuvant Immunotherapy in Renal Cell Carcinoma - Femke Burgers

Phase 2 Formula-01 Study Evaluates DV Combined With BCG for HER2-High NMIBC - Xingliang Tan

Clinical and Molecular Criteria for Aggressive Variant Prostate Cancer - Ana Aparicio

KIM-1 Biomarker Evaluated for Association with Outcomes in Advanced RCC Treatment - Wenxin Xu

PSMACare: Early Lutetium RLT in High-Risk nmCRPC - Fred Saad

KEYMAKER-U03 Substudy Compares Four Combinations to Standard Therapy - Cristina Suárez

Biomarker Analysis from the SunRISe-1 Trial in BCG-Unresponsive CIS - Félix Guerrero-Ramos

Optimizing Advanced Prostate Cancer Care: Balancing Intensification and Overtreatment - Gerhardt Attard

COSMIC-313 Correlative Analysis Links Specific T-Cell Subset to Improved PFS with Immunotherapy - Berkay Simsek

LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn

Phase 2 ALPACA Trial Evaluates Avelumab in Advanced Penile Cancer - Srikala Sridhar

Phase Ib/II Trial Combines Ciforadenant with Ipilimumab and Nivolumab in Frontline Kidney Cancer - Kathryn Beckermann

ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Prostate Cancer - Oliver Sartor

The Phase III ENZARAD Trial: Enzalutamide with Radiation and ADT in High-Risk Prostate Cancer - Paul Nguyen

A SEER Database Analysis of Real-World Survival Trends in Metastatic Prostate Cancer - Pedro Barata

Analysis of Patient-Reported Quality of Life from the AMPLITUDE Trial - Eleni Efstathiou

Feasibility of Using an RNA-Seq Biomarker to Assign Therapy in the OPTIC RCC Trial - Pedro Barata

PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal

EMBARK Trial Reports Overall Survival Benefit for Enzalutamide with ADT in High-Risk Non-Metastatic Prostate Cancer - Stephen Freedland

Phase III CAPItello-281 Trial Results for mHSPC with PTEN Loss - Karim Fizazi

CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George

Health-Related Quality of Life Outcomes from the NIAGARA Trial in Bladder Cancer - Michiel Van Der Heijden

Final Results of the SunRISe-4 Study in Muscle-Invasive Bladder Cancer - Andrea Necchi

Phase 2 Trial of Neoadjuvant Nivolumab and Visugromab in Bladder Cancer Patients - Andrea Necchi

Analysis of MRI Use in the Diagnostic Pathway for Bladder Cancer - Nicholas James

Evaluating Chemotherapy De-Escalation in First-Line Urothelial Carcinoma: DISCUS Trial - Enrique Grande

Pre-ESMO 2025 Highlights - Rashid Sayyid & Zachary Klaassen